Throughout the pandemic, health care providers had very few options for treating patients with COVID-19. Over time, some treatments have been shown to be ineffective, while others have proven themselves with enough evidence that they help to shorten illness and save lives. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. When administered to non-hospitalized patients as soon as possible after positive viral testing for SARSCoV-2 and within 10 days of symptom onset, monoclonal antibodies may reduce viral load, symptoms, and risk of hospitalizations and emergency room visits associated with COVID-19.
For more information on monoclonal antibody treatment, who is eligible and where to refer your patients visit the MSMS COVID-19 resource page for a list of resources with direct links.